News Releases
26 April 2022
Oncoc4 Announces Fast Track Designation Granted By The U.S. FDA For ONC-392 Monotherapy In PD(L)1-Resistant NSCLC
A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway
April 25, 2022, Rockville, Maryland -- OncoC4, Inc., a clinical stage biopharma company developing novel immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, the Company’s next-gen anti-CTLA-4 monoclonal antibody (mAb) that preserves the CTLA-4 immune checkpoint function, as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.
01 April 2022
Dr. Yang Liu Acknowledged as Top 20 Dynamic CEOs of 2022
ROCKVILLE, Md., Mar. 31, 2022 - The CEO Publication, a unique digital platform featuring the industry experts who have created ripples across various areas of expertise, has acknowledged Dr. Yang Liu, Chairman, CEO & CSO, OncoC4 — a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment — one among the “Top 20 Dynamic CEOs of 2022″ who is transforming the industry with his unique solutions. The CEO Publication has become a pioneering magazine owing to their unique coverage of news, articles & industry leaders concentrating on transforming various arenas.
15 March 2022
OncoC4 Recognized as a Top 10 Immunotherapy Solutions Providers
ROCKVILLE, Md., Mar. 15, 2022 - OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the "Top 10 Immunotherapy Solutions Providers - 2022".
18 February 2022
Dr. Pan Zheng of OncoC4 is Inducted into the 2022 College of Fellow of AIMBE
ROCKVILLE, Md., Feb. 18, 2022 - OncoC4, Inc. is elated to announce that its co-founder and Chief Medical Officer, Dr. Pan Zheng, has been selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.
09 November 2021
OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors
ROCKVILLE, Md., Nov. 09, 2021 -- OncoC4, Inc., a clinical stage biopharma company focusing on immuno-oncology of cancer, reports a summary of preliminary clinical data from the ongoing Phase Ia clinical trial (PRESERVE-001, NCT04140526) evaluating the safety, tolerability and clinical activity of ONC-392 in cancer patients. ONC-392 is the only clinically tested nextgen anti-CTLA-4 monoclonal antibody that through a unique mechanism recycles, instead of destroys, the CTLA-4 molecules thereby reducing immunotherapy-related toxicity induced by the CTLA-4 depletion while enhancing therapeutic activities.
27 May 2021
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
SHANGHAI and ROCKVILLE, Md., May 26, 2021 -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.